• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Advanced Viral Research Corp. Announces Completion of Accrual in First Part of Diabetes Study

Posted on: Friday, 12 May 2006, 09:07 CDT

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that it has completed enrollment of subjects in the first part of the Phase I study in Type 2 diabetic patients. In this study, 30 subjects with type 2 diabetes, being treated with sulfonylureas and/or metformin, were expected to be enrolled. The primary objective was to explore the effect of daily doses 4.0 ml of AVR118 given subcutaneously on blood glucose, as compared to subjects not receiving AVR118. All 30 subjects have been enrolled.

Earlier this year, the Company amended the protocol for this study to include an additional 12 subjects at a dose of 1.0 ml of AVR118 given subcutaneously daily for 15 days, followed by one week of dosing every other day. Accrual of the additional 12 patients is currently ongoing.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Source: Advanced Viral Research Corp.

Source: Business Wire

More News in this Category